TGN1412 drug molecule

TGN1412 drug molecule

A617/0170 Rights Managed

Request low-res file

530 pixels on longest edge, unwatermarked

Request/Download high-res file

Uncompressed file size: 49.8MB

Downloadable file size: 1,010.9KB

Price image Pricing

Please login to use the price calculator


Caption: TGN1412 drug molecule. Computer model showing the secondary structure of the drug TGN1412. This drug was shown to have serious side effects during a clinical trial in the UK in 2006 when it caused systemic failure in 6 volunteers. The drug is a monoclonal antibody that activates T cells by binding to CD28 receptors on the cell's surface. T cells are a type of white blood cell and a component of the body's immune system.

Release details: Model release not required. Property release not required.

Keywords: agonist, artwork, beta sheet, biochemical, biochemistry, cd28, cd28-supermab, chemical, chemistry, clinical trial, compound, compounds, computer artwork, computer model, controversial, drug, drug trial, effects, failure, illustration, immunomodulatory, medical, medicine, molecular, molecular model, molecule, molecules, monoclonal antibody, one, pharmacological, pharmacology, protein, proteins, secondary structure, sheets, side effect, single, tgn1412

Licence fees: A licence fee will be charged for any media (low or high resolution) used in your project.